Bioprocessing White Papers
-
Navigating Complex OSD Challenges With Predictive Insights
7/20/2026
Learn how predictive modeling, advanced material characterization, and data-driven process insights support manufacturing readiness and confident launch decisions.
-
Starting With The End In Mind
7/16/2026
Complex biologics need scalable, GMP-ready development from the start. Early decisions, scientific continuity, and strong partnerships help reduce delays and rework.
-
Negative Stain TEM For Viral Particle Characterization
7/8/2026
Standardized latex bead references combined with negative stain TEM provide precise viral particle characterization and consistent viral load quantification.
-
Enhancing Biopharmaceutical Production Through Advanced Mixing
6/30/2026
Eliminate particulate contamination and product degradation in downstream bioprocessing. Learn how frictionless, levitating impeller technology ensures low-shear mixing and high yields.
-
The Connectivity Crisis Blocking AI Deployment
6/30/2026
Disconnected systems and siloed data block analytics in life sciences manufacturing. Learn to bridge the infrastructure gap and build a connected foundation for scalable intelligence.
-
Evaluation Of Novel Process Indicators For Hydrogen Peroxide Decontamination
6/30/2026
Immediate, quantifiable verification replaces seven-day incubation periods. Discover how enzyme-based indicators optimize hydrogen peroxide decontamination.
-
Engineering The Future Of Antibody-Drug Conjugates
6/26/2026
As ADCs expand into broader use, upstream process design is becoming a competitive advantage. Discover how smarter media strategies and data-driven decision-making are helping teams reduce risk.
-
Exploring The Future Of Cell Expansion In Cell Therapy Manufacturing
6/26/2026
As cell therapy scales, success depends on more than clinical promise. Smarter expansion strategies, automation, and flexible manufacturing platforms are becoming critical for improving consistency.
-
Delivering Critical Therapies With Speed And Safety
6/26/2026
Faster approvals depend on treating regulation as part of development, not the finish line. See how early quality planning and strong agency communication can move therapies toward patients sooner.
-
Context-First Data For Trustworthy AI In Biopharma
6/26/2026
Bridge the gap between AI experimentation and enterprise value. Learn how capturing structured, semantically rich data at the point of origin builds regulator-credible AI pipelines.